Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.60 |
| ▸ | CDC25B | P30305 | 8/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.53 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.50 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.50 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.50 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290978 | 1.00 | PTPN1 (0.60) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL8824495 | 1.00 | PTPN1 (0.60) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL2292504 | 1.00 | PTPN1 (0.60) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL12380701 | 1.00 | PTPN1 (0.60) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL2292501 | 1.00 | PTPN1 (0.60) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL12380715 | 0.98 | PTPN1 (0.58) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL12380707 | 0.95 | PTPN1 (0.56) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL2293239 | 0.95 | PTPN1 (0.56) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL2293235 | 0.95 | PTPN1 (0.56) | PTPN1CDC25BNT5EPTPN2PTPN11 | |
| SCHEMBL2290632 | 0.95 | PTPN1 (0.56) | PTPN1CDC25BNT5EPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989602-B2 | having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity; asthma, allergic rhinitis, dermatitis, psoriasis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | UNIVERSITY OF OTAGO (NZ) | 2008-10-09 | — | — | US | disclosed |
| WO-2005049631-A1 | SYNTHETIC MOLECULES HAVING IMMUNE ACTIVITY | THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249037-A1 | Synthetic Molecules Having Immune Activity | ALG1, PAG1, SIGLEC7 | PTPN1 1017/4885CDC25B 1097/4885NT5E 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.